ID   NOK-SI
AC   CVCL_BW57
SY   NOKSI; NOKsi; Normal Oral Keratinocytes-Spontaneously Immortalized
DR   Cosmic; 2296312
DR   Wikidata; Q54930891
RX   PubMed=20463891;
RX   PubMed=25275298;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HaCaT derivative (ICLAC). Originally thought to originate from normal oral keratinocytes from a female donor.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00589.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=25275298).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Back, skin, epidermis; UBERON=UBERON_0001068+UBERON_0001003.
CC   Cell type: Keratinocyte; CL=CL_0000312.
ST   Source(s): PubMed=25275298
ST   Amelogenin: X
ST   CSF1PO: 9,11
ST   D13S317: 10,12
ST   D16S539: 9,12
ST   D18S51: 12
ST   D21S11: 28,30.2
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 14
ST   FGA: 24
ST   Penta D: 11,13
ST   Penta E: 7,12
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 16,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0038 ! HaCaT
SX   Male
AG   62Y
CA   Spontaneously immortalized cell line
DT   Created: 02-05-16; Last updated: 29-06-23; Version: 10
//
RX   PubMed=20463891; DOI=10.1371/journal.pone.0010503;
RA   Castilho R.M., Squarize C.H., Leelahavanichkul K., Zheng Y., Bugge T.,
RA   Gutkind J.S.;
RT   "Rac1 is required for epithelial stem cell function during dermal and
RT   oral mucosal wound healing but not for tissue homeostasis in mice.";
RL   PLoS ONE 5:E10503-E10503(2010).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//